Bannerbild German Brest Group

Overview of Publications 2018

Schneeweiss A, Möbus V, Tesch H, Hanusch C, Denkert C, et al. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. Eur J Cancer. 2019 (manuscript accepted 2018);106:181-192.

Bischoff J, Barinoff J, Mundhenke C, Bauerschlag DO, Costa S-D, et al. A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA). Anti-Cancer Drugs 2018 (manuscript accepted 2018).

von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2018 Dec 5. [Epub ahead of print] 

Matikas A, Foukakis T, Moebus V, Greil R, Bengtsson NO, et al. Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: Further results from the prospective PANTHER study with focus on obese patients. Ann Oncol. 2018 Oct 24 [Epub ahead of print]

Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, et al. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. J Clin Oncol. 2018; 36:1981-1990

Loibl S, Weber KE, Timms KM, Elkin EP, Hahnen E, et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response - final results from GeparSixto. Ann Oncol. 2018;29:2341-2347.

Liedtke C, Kolberg HC, Kerschke L, Görlich D, Bauerfeind I, et al. Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST). Clin Exp Metastasis. 2018;35:777-783.

Stevic I, Müller V, Weber K, Fasching PA, Karn T, et al. Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Med. 2018;16:179.

Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, et al; SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018; 379:122-137

Lambertini M, Di Maio M, Pagani O, Curigliano G, Poggio F, et al. The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. Breast. 2018;42:41-49

Witzel I, Laakmann E, Weide R, Neunhöffer T, Park-Simon TJ, et al. Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry. Eur J Cancer. 2018;102:1-9.

Nekljudova V, Loibl S, von Minckwitz G, Schneeweiss A, Glück S, et al. Trial-level prediction of long-term outcome based on pathologic complete response (pCR) after neoadjuvant chemotherapy for early-stage breast cancer (EBC). Contemp Clin Trials. 2018 71:194-198.

Wu L, Shi W, Long J, Guo X, Michailidou K, et al. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nat Genet. 2018; 50:968-978.

Fasching PA, Loibl S, Hu C, Hart SN, Shimelis H, et al. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J Clin Oncol. 2018; 36:2281-2287.

von Waldenfels G, Loibl S, Furlanetto J, Machleidt A, Lederer B, et al. Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials. Oncotarget. 2018;9(20):15168-15179.

Loibl S, Weber K, Huober J, Krappmann K, Marmé F, et al. Risk assessment after neoadjuvant chemotherapy in luminal breast cancer using a clinico-molecular predictor. Clin Cancer Res. 2018; 24:3358-3365.

Untch M, von Minckwitz G, Gerber B, Schem C, Rezai M, et al. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). J Clin Oncol. 2018; 36:1308-1316.

Engel C, Rhiem K, Hahnen E, Loibl S, Weber KE, et al. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. BMC Cancer. 2018; 18:265

Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018; 19:497-509.

Ingle JN, Kalari KR, Wickerham DL, von Minckwitz G, Fasching PA, et al. Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab. Pharmacogenet Genomics. 2018;28:147-152.
Möbus V, Jackisch C, Lück HJ, du Bois A, Thomssen C, et al. Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. Ann Oncol. 2018;29:178-185.
Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, et al. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. J Natl Cancer Inst. 2018; 110:560-567.


Denkert C, Loibl S, Budczies J, Wienert S, Klauschen F. [Standardized determination of tumor-infiltrating lymphocytes in breast cancer : A prognostic marker for histological diagnosis]. Der Pathologe. 2018; 39:520-531.

Klauschen F, Müller KR, Binder A, Bockmayr M, Hägele M, et al. Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. Semin Cancer Biol. 2018;52(Pt 2):151-157.

Tancredi R, Furlanetto J, Loibl S. Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature. Oncologist. 2018; 23:974-981.

Duchnowska R, Loibl S, Jassem J. Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. Cancer Treat Rev. 2018;67:71-77.


GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd